BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

14788

532872

SPARC

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SUN PHARMA ADV.RES.CO.LTD performance

Today’s low

Today’s high

₹ 145.10 ₹ 149.45
₹ 145.95

52 week low

52 week high

₹ 109.30 ₹ 258.00
₹ 145.95

Open Price

₹ 148.50

Prev. Close

₹ 148.45

Volume (Shares)

354129.00

Total traded value

₹ 516.85

Upper Circuit

₹ 178.14

Lower Circuit

₹ 118.76

info

SUN PHARMA ADV.RES.CO.LTD Share Price Update

As of the latest trading session, SUN PHARMA ADV.RES.CO.LTD share price is currently at ₹ 146.01, which is down by ₹ -2.44 from its previous closing. Today, the stock has fluctuated between ₹ 145.10 and ₹ 149.45. Over the past year, SUN PHARMA ADV.RES.CO.LTD has achieved a return of -37.17 %. In the last month alone, the return has been -0.23 %. Read More...

SUN PHARMA ADV.RES.CO.LTD fundamentals


  • Market cap (Cr)

    4,738.34

  • P/E Ratio (TTM)

    -12.11

  • Beta

    1.27

  • Book Value / share

    3.84

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -79.71

info icon alternate text
  • Market cap (Cr)

    4,736.39

  • P/E Ratio (TTM)

    -12.11

  • Beta

    1.27

  • Book Value / share

    3.84

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -79.71

info icon alternate text

SUN PHARMA ADV.RES.CO.LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 14.91
Operating Expense 94.81
Net Profit -79.71
Net Profit Margin (%) -534.60
Earnings Per Share (EPS) -2.46
EBITDA -74.19
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 12.86
Operating Expense 120.59
Net Profit -107.69
Net Profit Margin (%) -837.40
Earnings Per Share (EPS) -3.32
EBITDA -103.81
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 16.81
Operating Expense 115.21
Net Profit -96.84
Net Profit Margin (%) -576.08
Earnings Per Share (EPS) -2.98
EBITDA -93.56
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 16.56
Operating Expense 127.64
Net Profit -106.69
Net Profit Margin (%) -644.26
Earnings Per Share (EPS) -3.29
EBITDA -103.12
Effective Tax Rate (%) 0.00
Particulars DEC 2023 (Values in Cr)
Revenue 13.86
Operating Expense 119.90
Net Profit -99.65
Net Profit Margin (%) -718.97
Earnings Per Share (EPS) -3.07
EBITDA -96.23
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 75.55
Operating Expense 493.13
Net Profit -388.11
Net Profit Margin (%) -513.71
Earnings Per Share (EPS) -11.96
EBITDA -374.32
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 238.78
Operating Expense 472.24
Net Profit -222.58
Net Profit Margin (%) -93.21
Earnings Per Share (EPS) -7.82
EBITDA -203.18
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 137.25
Operating Expense 347.49
Net Profit -203.40
Net Profit Margin (%) -148.19
Earnings Per Share (EPS) -7.73
EBITDA -179.91
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 252.96
Operating Expense 409.51
Net Profit -151.14
Net Profit Margin (%) -59.74
Earnings Per Share (EPS) -5.77
EBITDA -129.57
Effective Tax Rate (%) 0.00
Particulars MAR 2020 (Values in Cr)
Revenue 76.82
Operating Expense 398.98
Net Profit -312.40
Net Profit Margin (%) -406.66
Earnings Per Share (EPS) -11.92
EBITDA -300.24
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 3.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.12
EBITDA Margin -493.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.80
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.03
EBITDA Margin -85.09
Particulars MAR 2024 (Values in Cr)
Book Value / Share 3.85
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.11
EBITDA Margin -495.46
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.80
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.17
EBITDA Margin -85.09
Particulars MAR 2022 (Values in Cr)
Book Value / Share -7.47
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -131.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share -6.42
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -51.22
Particulars MAR 2020 (Values in Cr)
Book Value / Share -0.71
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.25
EBITDA Margin -390.90
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 155.32
Total Assets 515.04
Total Liabilities 515.04
Total Equity 125.75
Share Outstanding 324521588
Price to Book Ratio 96.09
Return on Assets (%) -75.18
Return on Capital (%) -224.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 111.57
Total Assets 830.12
Total Liabilities 830.12
Total Equity 512.77
Share Outstanding 324521588
Price to Book Ratio 11.36
Return on Assets (%) -26.81
Return on Capital (%) -43.4
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 155.06
Total Assets 486.33
Total Liabilities 486.33
Total Equity 124.85
Share Outstanding 324521588
Price to Book Ratio 96.09
Return on Assets (%) -79.80
Return on Capital (%) -225.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 111.57
Total Assets 830.12
Total Liabilities 830.12
Total Equity 512.77
Share Outstanding 324521588
Price to Book Ratio 11.36
Return on Assets (%) -26.81
Return on Capital (%) -43.4
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.22
Total Assets 280.08
Total Liabilities 280.08
Total Equity 31.22
Share Outstanding 271878966
Price to Book Ratio -39.74
Return on Assets (%) -72.61
Return on Capital (%) -191.47
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.31
Total Assets 229.68
Total Liabilities 229.68
Total Equity -168.25
Share Outstanding 262047506
Price to Book Ratio -22.07
Return on Assets (%) -65.80
Return on Capital (%) -242.62
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.45
Total Assets 272.56
Total Liabilities 272.56
Total Equity -18.63
Share Outstanding 262047506
Price to Book Ratio -135.92
Return on Assets (%) -114.61
Return on Capital (%) -654.39
Particulars MAR 2024 (Values in Cr)
Net Income -386.83
Cash from Operations -425.07
Cash from Investing 391.52
Cash from Financing 42.40
Net change in Cash 4.74
Free Cash Flow -398.56
Particulars MAR 2023 (Values in Cr)
Net Income -222.58
Cash from Operations -74.48
Cash from Investing -548.27
Cash from Financing 616.75
Net change in Cash -0.64
Free Cash Flow -59.09
Particulars MAR 2024 (Values in Cr)
Net Income -388.10
Cash from Operations -425.31
Cash from Investing 391.11
Cash from Financing 42.79
Net change in Cash 4.47
Free Cash Flow -398.80
Particulars MAR 2023 (Values in Cr)
Net Income -222.58
Cash from Operations -74.48
Cash from Investing -548.27
Cash from Financing 616.75
Net change in Cash -0.64
Free Cash Flow -59.09
Particulars MAR 2022 (Values in Cr)
Net Income -203.39
Cash from Operations -212.77
Cash from Investing -29.16
Cash from Financing 229.32
Net change in Cash -8.07
Free Cash Flow -180.09
Particulars MAR 2021 (Values in Cr)
Net Income -151.13
Cash from Operations -150.26
Cash from Investing 1.56
Cash from Financing 159.28
Net change in Cash 8.95
Free Cash Flow -144.26
Particulars MAR 2020 (Values in Cr)
Net Income -312.40
Cash from Operations -200.94
Cash from Investing 155.34
Cash from Financing 55.46
Net change in Cash 0.00
Free Cash Flow -146.90
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

SUN PHARMA ADV.RES.CO.LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
145.95 -1.68 redarrow
red-green-graph indicator
15 Bearish
1 Bullish
  • 5 Days 148.90
  • 26 Days 147.00
  • 10 Days 149.40
  • 50 Days 148.50
  • 12 Days 149.20
  • 100 Days 162.00
  • 20 Days 147.80
  • 200 Days 185.60
149.88 PIVOT

First Support

146.22

First Resistance

152.11

Second Support

143.99

Second Resistance

155.77

Third Support

140.33

Third Resistance

158.00

RSI

48.65

ADX

35.49

MACD

2.16

Williams % R

-74.70

Commodity Channel Index (CCI)

-38.23

Date

2025-04-30

Week

224210.00

Same Day

131497.00

Month

271951.00

1 Year

1.28

3 Year

1.11

Over 1 Month

-0.23%

down

Over 1 Year

-37.17%

down

Over 3 Months

-7.52%

down

Over 3 Years

-17.60%

down

Over 6 Months

-32.36%

down

Over 5 Years

2.08%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SUN PHARMA ADV.RES.CO.LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
31.75%
Promoter Holdings
65.67%
FII
1.44%
DII
1.13%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shanghvi Finance Private Ltd 1.37211787E8 (42.28%) Shareholding of Promoter and Promoter Group
Dilip.s.shanghvi 6.181066E7 (19.05%) Shareholding of Promoter and Promoter Group
Sun Pharmaceutical Industries Key Employees Benefit Trust 1.0317377E7 (3.18%) Public Shareholding
Lakshdeep Investments & Finance (p) Ltd. 6033835.0 (1.86%) Public Shareholding
Aditya Medisales Limited 4888126.0 (1.51%) Shareholding of Promoter and Promoter Group
Raksha Sudhir Valia 4145231.0 (1.28%) Shareholding of Promoter and Promoter Group
Vijay Mohanlal Parekh 3661304.0 (1.13%) Public Shareholding
Paresh Mohanlal Parekh 3646837.0 (1.12%) Public Shareholding
Enam Holdings Pvt Ltd 3370786.0 (1.04%) Public Shareholding
Sudhir Vrundavandas Valia 1833951.0 (0.57%) Shareholding of Promoter and Promoter Group
Unimed Investments Limited 1267963.0 (0.39%) Shareholding of Promoter and Promoter Group
Vibha Dilip Shanghvi 1063236.0 (0.33%) Shareholding of Promoter and Promoter Group
Vidhi Dilip Shanghvi 344081.0 (0.11%) Shareholding of Promoter and Promoter Group
Aalok Dilip Shanghvi 350162.0 (0.11%) Shareholding of Promoter and Promoter Group
Shanghvi Family & Friends Benefit Trust 154922.0 (0.05%) Shareholding of Promoter and Promoter Group
Kumud Shantilal Shanghvi 38795.0 (0.01%) Shareholding of Promoter and Promoter Group
Gujarat Sun Pharmaceutical Industries Pvt Ltd 1751.0 (0.0%) Shareholding of Promoter and Promoter Group
Sanghvi Properties Private Limited 1887.0 (0.0%) Shareholding of Promoter and Promoter Group
Flamboyawer Finance Private Limited 2543.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

SUN PHARMA ADV.RES.CO.LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

SUN PHARMA ADV.RES.CO.LTD Share Price

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems. The Company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS).

Sun Pharmaceutical Advanced Research Company Ltd was incorporated on March 1, 2006 as an innovative and development company. They commenced operations on March 22, 2006. As per Scheme of Arrangement, all assets and liabilities of the Innovative Research & Development business including Novel Drug Delivery System (NDDS) division of Sun Pharmaceuticals Industries' Research & Development undertaking stands transferred and vested in the Company with effect from Appointed date on February 28, 2007. The demerger became effective on March 28, 2007. On Scheme being effective, the Company ceased to be subsidiary of Sun Pharmaceutical Industries Ltd., and the demerged Company.

During the year 2009-10, the Department of Scientific and Industrial Research (DSIR), Government of India sanctioned a 15 year unsecured soft loan under their Drug and Pharmaceutical Research Programme for a project of the Company.

During 2011, the Company announced USFDA approval for DOCEFREZ (docetaxel) for Injection'. During 2014, the Company announced Govt. of India approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN).

On 1 December 2014, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for Latanoprost BAK-free eyedrops. While the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling and other deficiencies for processing the NDA.

On 4 March 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries Ltd at its Halol (Gujarat) facility in India.

On 9 June 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) and Sun Pharmaceutical Industries Ltd. announced that SPARC has licensed out Xelpros (Latanoprost BAK-free eye drops) to a subsidiary of Sun Pharma for the US market.

On 1 August 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops. SPARC submitted a response to an earlier CRL it had received from the USFDA, wherein no additional preclinical or clinical data was required. While the USFDA has accepted the clarifications and changes to the labeling, SPARC has now received another CRL from the USFDA seeking minor changes to the proposed labeling. SPARC hopes to address these requirements soon. This product is proposed to be manufactured at Sun Pharmaceutical Industries Ltd (SPIL)'s Halol facility and the USFDA has indicated that a satisfactory resolution of the cGMP deficiencies at this facility is a prerequisite for the final approval of Xelpros. SPARC had recently out-licensed this product to a subsidiary of Sun Pharmaceutical Industries Ltd (SPIL).

On 25 September 2015, Sun Pharma Advanced Research Company Ltd. announced that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). SPARC had earlier received a final approval from USFDA in March 2015 for this product and was evaluating several marketing partners for commercialization. However SPARC has now received a CRL from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility was not acceptable on the date of approval. Elepsia XR is proposed to be manufactured at Sun Pharmaceutical Industries Ltd (SPIL)'s Halol facility. SPIL is working with USFDA in resolving the cGMP deviations at the facility and has taken several corrective measures.

On 31 December 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the management expects a possible further delay in the projected royalty income for the company from XELPROS (Latanoprost Ophthalmic Emulsion) and Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). This follows a warning letter to Sun Pharmaceutical Industries Ltd (SPIL) from the USFDA for its facility located at Halol, Gujarat in India. XELPROS and Elepsia XR are proposed to be manufactured at (SPIL)'s Halol facility.

The Board of Directors of Sun Pharma Advanced Research Company Ltd. (SPARC) at its meeting held on 5 March 2016 approved rights issue of equity shares in the ratio of 5 equity shares for every 116 equity shares held as on the record date. The rights issue has been priced at Rs 245 per share. The company will raise upto Rs 250 crore from the rights issue.

On 18 July 2016, Sun Pharma Advanced Research Company Ltd. (SPARC) and Sun Pharmaceutical Industries Ltd. announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam Extended Release tablets). As per the agreement, SPARC will license ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market. SPARC will receive an up-front payment of US$10 million from Sun Pharma. It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XR.

On 22 December 2016, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the company has received a Complete Response Letter (CRL) from the USFDA for the New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops. The CRL references the recent inspection of Sun Pharmaceutical Industries Ltd.'s Halol manufacturing site by USFDA and indicates that satisfactory resolution of the deficiencies identified during the inspection is required before the final approval of Xelpros. There are no requirements of any additional data from USFDA in the CRL. SPARC had out-licensed Xelpros to a subsidiary of Sun Pharmaceutical Industries Ltd. in June 2015.

On 19 May 2017, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the company has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.

On 14 September 2018, Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) announced U.S. Food and Drug Administration (USFDA) approval for the New Drug Application (NDA) of XELPROS (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure (IOP, or pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension. This approval is from Sun Pharma's Halol (Gujarat, India) facility. Sun Pharma in-licensed XELPROS from SPARC in June 2015 and this approval will trigger a milestone payment to SPARC. SPARC is also eligible for milestone payments and royalties on commercialization of XELPROS in the US.

In FY 2019-20, Company executed its 1st in-licensing agreement with Bioprojet (France) obtaining exclusive global rights of SCD-044. It also established first commercial partnership with China Medical Systems Ltd., out-licensing commercial rights of five assets (XelprosTM, ElepsiaTM, TaclantisTM, PDP-716 and SDN-037). SPARC's vodobatinib was granted orphan drug designation for treatment of CML. During the year, SPARC also commenced the investigator initiated study of SCC-138 in Lewy Body Dementia. It completed Phase I study of SCD-044.

During FY 2021-22, Company progressed on multiple collaborative projects and also acquired exclusive rights for antibody against a unique oncology target from Biomodifying Inc. It licensed the commercialization rights for PDP-716 and SDN-037 to Visiox Pharma, a specialty pharma company focused on ophthalmology. The commercialization of ElepsiaTM XR commenced in 2021. It licensed the global (excluding India and greater China) commercialization rights to Visiox Pharma.

On January 06, 2023 the Company had allotted 4,91,92,121 equity shares against the conversion of equal number of warrants issued on preferential basis. Consequent to the said allotment, Shanghvi Finance Private Limited (SFPL) has ceased to be the Company's Holding Company effective from the said date as its percentage shareholding along with its subsidiaries in the Company reduced from 52.07% to 44.18%.

During FY23, SPARC along with Visiox completed the NDA submission to the USFDA in August 2023. SezabyTM Commercialization was commenced by Sun Pharma in Jan 2023.

Parent organization Sun Pharma
NSE symbol SPARC
Founded 2006
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Sun Pharma Advanced Research Company Ltd?

Answer Field

The share price of Sun Pharma Advanced Research Company Ltd for NSE is ₹ 146.01 and for BSE is ₹ 145.95.

What is the Market Cap of Sun Pharma Advanced Research Company Ltd?

Answer Field

The market cap of Sun Pharma Advanced Research Company Ltd for NSE is ₹ 47,38.34 Cr. and for BSE is ₹ 47,36.39 Cr. as of now.

What is the 52 Week High and Low of Sun Pharma Advanced Research Company Ltd?

Answer Field

The 52 Week High and Low of Sun Pharma Advanced Research Company Ltd for NSE is ₹ 258.00 and ₹ 109.30 and for BSE is ₹ 257.70 and ₹ 109.20.

How to Buy Sun Pharma Advanced Research Company Ltd share?

Answer Field

You can trade in Sun Pharma Advanced Research Company Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Sun Pharma Advanced Research Company Ltd?

Answer Field

The 1 year returns on the stock has been -37.17%.

What is the Current Share Price of Sun Pharma Advanced Research Company Ltd?

Answer Field

Sun Pharma Advanced Research Company Ltd share price is for NSE ₹ 146.01 & for BSE ₹ 145.95 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Sun Pharma Advanced Research Company Ltd Share?

Answer Field

The market cap of Sun Pharma Advanced Research Company Ltd for NSE ₹ 47,38.34 & for BSE ₹ 47,36.39 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Sun Pharma Advanced Research Company Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Sun Pharma Advanced Research Company Ltd share is -12.11.

What is the PB ratio of Sun Pharma Advanced Research Company Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Sun Pharma Advanced Research Company Ltd share is 3.84.

How to Buy Sun Pharma Advanced Research Company Ltd Share?

Answer Field

You can trade in Sun Pharma Advanced Research Company Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Sun Pharma Advanced Research Company Ltd Share on Bajaj Broking App?

Answer Field

To buy Sun Pharma Advanced Research Company Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Sun Pharma Advanced Research Company Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|